4.7 Review

PARP and other prospective targets for poisoning cancer cell metabolism

Journal

BIOCHEMICAL PHARMACOLOGY
Volume 92, Issue 1, Pages 164-171

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2014.08.026

Keywords

Autophagy; Mitochondria; NADPH; PARP-1; Sirtuin

Funding

  1. Assistance publique des hopitaux de Paris, France
  2. Action Lions Vaincre le Cancer, Luxembourg
  3. Associazione Italiana per la Ricerca sul Cancro (AIRC)
  4. European Commission (ArtForce)
  5. Agence National de la Recherche (ANR)
  6. Ligue Nationale contre le Cancer
  7. Fondation pour la Recherche Medicale (FRM)
  8. Institut National du Cancer (INCa)
  9. Association pour la Recherche sur le Cancer (ARC)
  10. LabEx Immuno-Oncologie
  11. Fondation de France
  12. Fondation Bettencourt-Schueller
  13. AXA Chair for Longevity Research
  14. Canceropelle Ile-de-France
  15. Paris Alliance of Cancer Research Institutes (PACRI)
  16. Cancer Research for Personalized Medicine (CARPEM)

Ask authors/readers for more resources

Increasing evidence indicates that cancer cells rewire their metabolism during tumorigenesis. The high intracellular levels of lactate and reactive oxygen species (ROS) generated during enhanced aerobic glycolysis and mitochondrial oxidative phosphorylation respectively led to oxidative stress. The detoxification of these accumulating metabolites and the equilibrium between reduced and oxidized nicotine adenine dinucleotide (NADH and NAD(+)) are two prominent mechanisms regulating redox status and hence energy homeostasis in tumors. Targeting both processes may thus be selectively cytotoxic for cancer cells. In this context, the impact of poly(ADP-ribose) polymerase (PARP) inhibitors, a class of anticancer agents employed for the treatment of DNA repair deficient tumors, on energy homeostasis and mitochondrial respiration regulation has potential clinical implications. Here we provide an overview of the metabolic reprogramming occurring in cancer cells and discuss the translational perspectives of targeting tumor metabolism and redox balance for antineoplastic therapy. (C) 2014 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available